News

July 21, 2016

Pink Sheet

Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

By Catherine Kelly

J&J plans to rely on its broad portfolio to contract favorably in a ‘post-biosimilar world,’ but cross-category bundling is generally discouraged by payers.